ELDN (Eledon Pharmaceuticals, Inc. Common Stock) Stock Analysis - AI Report

Eledon Pharmaceuticals, Inc. Common Stock (ELDN) is a publicly traded Healthcare sector company. As of May 21, 2026, ELDN trades at $3.88 with a market cap of $276.33M and a P/E ratio of -7.20. ELDN moved +6.98% today. Year to date, ELDN is +132.73%; over the trailing twelve months it is +25.49%. Its 52-week range spans $1.35 to $5.54. Analyst consensus is strong buy with an average price target of $8.00. Rallies surfaces ELDN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the AI research view on ELDN?

Rallies AI research for ELDN combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.

ELDN Key Metrics

Key financial metrics for ELDN
MetricValue
Price$3.88
Market Cap$276.33M
P/E Ratio-7.20
EPS$-0.52
Dividend Yield0.00%
52-Week High$5.54
52-Week Low$1.35
Volume1
Avg Volume0
Revenue (TTM)$0
Net Income$-45.62M
Gross Margin0.00%

Latest ELDN News

ELDN Analyst Consensus

3 analysts cover ELDN: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.00.

Common questions about ELDN

What is the AI research view on ELDN?
Rallies AI research for ELDN combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for ELDN?
Rallies AI research for ELDN combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is ELDN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ELDN. It does not provide personalized investment advice.
ELDN

ELDN